Pfizer and BioNTech Announces Its Vaccine Is Useless 11 Months After Dosing

Description

by Alex Berenson via: Unreported Truths



Well, that's not how they phrased it.

But it is the only reasonable way to read their press release claiming that the booster is 95% effective.

Remember. The booster is given to people who have RECEIVED the vaccine. (That's why it's a booster, right?)

And when they tested a booster against a placebo in those people, they found a 95% reduction in disease in people who received the booster (for a total of 11 weeks after they received the booster, excluding the first week, because science – by which I mean because including that week would not help their results).

95%!

Where have you heard that figure before? Oh yeah, it is EXACTLY the same relative risk reduction they claimed in the pivotal trial last year, when they tested the INITIAL dose against placebo.

The only reasonable read is that the booster is providing (temporary) protection similar to the first twodose series (temporarily) did AGAINST PLACEBO. But these are VACCINATED people.

So where's the protection from the initial two doses?

There is ONE difference, though. The ABSOLUTE risk appeared at least two to three times higher in the vaccinated people in this trial than in UNVACCINATED people in the initial trial – 110 infections in 5,000 people in 10 weeks, compared to 162 infections in 20,000 people in about the same period.

Because vaccines work.

If you are vaccinated, get ready to take boosters forever.

By the way, the press release includes NO specific safety data.

Yay Pfizer!



Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

- First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain
- In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profile
- Companies plan to submit these data to FDA, EMA and other regulatory agencies to